General Toxicity Notes
May cause excessive sedation and encephalopathy in ESRD.
Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
4-10/No data
Plasma Protein Binding %
96
Volume Of Distribution L/Kg
1.3-1.5
Dose For Normal Renal Function
30 mg hs
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. Drug Saf. 1991; 6: 247-65. [PMID: 1888441] / Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry. 1991; 52 Suppl: 4-10. [PMID: 1680125] / Greenblatt DJ. Pharmacokinetics and pharmacodynamics. Hosp Pract (Off Ed). 1990; 25 Suppl 2: 9-15; discussion 16-8. [PMID: 2114417] / Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. Arch Gen Psychiatry. 1989; 46: 326-32. [PMID: 2564763] / Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, et al. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. Clin Pharmacol Ther. 1985; 37: 453-9. [PMID: 2858279]